These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26987935)

  • 21. [Prevention of joint damage in hemophilic children with early prophylaxis].
    Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
    Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A.
    Matysiak M; Bobrowska H; Balwierz W; Chybicka A; Kowalczyk JR; Shaikh-Zaidi R; Gillanders K; Dash CH
    Haemophilia; 2011 Sep; 17(5):737-42. PubMed ID: 21699629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A.
    Fischer K; Lewandowski D; Janssen MP
    Haemophilia; 2016 Sep; 22(5):e375-82. PubMed ID: 27353496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
    Saxena K; Lalezari S; Oldenburg J; Tseneklidou-Stoeter D; Beckmann H; Yoon M; Maas Enriquez M
    Haemophilia; 2016 Sep; 22(5):706-12. PubMed ID: 27339736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.
    Feldman BM; Pai M; Rivard GE; Israels S; Poon MC; Demers C; Robinson S; Luke KH; Wu JK; Gill K; Lillicrap D; Babyn P; McLimont M; Blanchette VS;
    J Thromb Haemost; 2006 Jun; 4(6):1228-36. PubMed ID: 16706965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Forum on: the role of recombinant factor VIII in children with severe haemophilia A.
    Franchini M; Coppola A; Molinari AC; Santoro C; Schinco P; Speciale V; Tagliaferri A
    Haemophilia; 2009 Mar; 15(2):578-86. PubMed ID: 19187188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
    Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
    Cheng X; Li P; Chen Z; Zhang N; Zhen Y; Zhao L; Wang X; Wu R
    Haemophilia; 2018 Jan; 24(1):120-125. PubMed ID: 29194866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.
    Tang L; Wu R; Sun J; Zhang X; Feng X; Zhang X; Luke KH; Poon MC
    Haemophilia; 2013 Jan; 19(1):27-34. PubMed ID: 23231016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient powered prophylaxis: A 12-month study of individualized prophylaxis in adults with severe haemophilia A.
    Sun HL; McIntosh KA; Squire SJ; Yang M; Bartholomew C; Gue DS; Camp PG; Jackson SC
    Haemophilia; 2017 Nov; 23(6):877-883. PubMed ID: 28851133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment.
    Wu R; Sun J; Xiao J; Liu Y; Xue F; Wang H; Tang L; Zhao Y; Li K; Yang R; Hu Y; Luke KH; Poon MC; Blanchette VS; Usuba K; Young NL
    Haemophilia; 2017 May; 23(3):430-436. PubMed ID: 28345299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.
    Vepsäläinen K; Lassila R; Arola M; Huttunen P; Koskinen S; Ljung R; Lähteenmäki P; Möttönen M; Riikonen P
    Haemophilia; 2016 Sep; 22(5):721-9. PubMed ID: 27339837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
    Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
    Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Joint Aspiration for Acute Hemarthrosis in Children Receiving Factor VIII Prophylaxis for Severe Hemophilia: 11-year Safety Data.
    Manners PJ; Price P; Buurman D; Lewin B; Smith B; Cole CH
    J Rheumatol; 2015 May; 42(5):885-90. PubMed ID: 25729030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A long term outcomes analysis of severe haemophilia A boys receiving 4 years prophylaxis on the Chinese Haemophilia Individualized escalating low dose Prophylaxis (CHIPS).
    Yao W; Ai D; Zhang Q; Li X; Zhou M; Zhang N; Yang S; Chen Z; Zhen Y; Luke KH; Wu R
    Thromb Res; 2024 Sep; 241():109110. PubMed ID: 39116483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is Low Dose a New Dose to Initiate Hemophilia A Prophylaxis? - A Systematic Study in Eastern India.
    Gulshan S; Mandal PK; Phukan A; Baul S; De R; Dolai TK; Chakrabarti P
    Indian J Pediatr; 2020 May; 87(5):345-352. PubMed ID: 32048222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
    Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
    Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term tolerability, immunogenicity and efficacy of Nuwiq
    Klukowska A; Szczepański T; Vdovin V; Knaub S; Bichler J; Jansen M; Dzhunova I; Liesner RJ
    Haemophilia; 2018 Jul; 24(4):595-603. PubMed ID: 29582516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.